Soleno Therapeutics (NASDAQ:SLNO) Trading 10% Higher – Here’s Why

Soleno Therapeutics, Inc. (NASDAQ:SLNO)’s stock price was up 10% during trading on Tuesday . The company traded as high as $32.81 and last traded at $33.48. Approximately 147,595 shares changed hands during mid-day trading, a decline of 91% from the average daily volume of 1,587,466 shares. The stock had previously closed at $30.44.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Bullish take: an analyst/market commentary piece said Soleno remains attractive despite a slower-than-expected U.S. launch ramp for DCCR, supporting investor optimism about longer‑term commercial potential. Soleno remains attractive despite slower launch
• Positive Sentiment: Elevated bullish options activity: unusually large call buying was reported on 3/31 (about 2,940 calls), suggesting speculative or hedged bullish interest that can amplify upside and intraday volume. Options activity report
• Neutral Sentiment: Procedural notice: multiple investor‑rights firms are reminding eligible purchasers about the May 5, 2026 deadline to seek lead‑plaintiff status — a routine step in active securities litigation that increases outreach but is procedural. Kirby McInerney reminder re: May 5 deadline
• Negative Sentiment: Active litigation filings: several firms (Hagens Berman, Kessler Topaz, others) have publicized securities class actions alleging material misstatements/omissions about Soleno’s Phase 3 program and DCCR launch issues — these claims increase legal/financial risk and can pressure the stock. Hagens Berman class action filing
• Negative Sentiment: Allegations of more serious misconduct: some notices (e.g., Levi & Korsinsky) frame claims as involving misrepresentations about clinical‑trial integrity and safety — if those allegations gain traction, regulatory scrutiny or larger settlements could follow. Levi & Korsinsky investor alert

Analyst Upgrades and Downgrades

SLNO has been the topic of several research reports. Wolfe Research set a $60.00 price objective on shares of Soleno Therapeutics in a report on Monday, January 12th. HC Wainwright decreased their target price on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. TD Cowen dropped their price target on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Oppenheimer cut their price target on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a report on Wednesday, March 18th. Finally, Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research note on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $102.00.

Soleno Therapeutics Stock Performance

The stock has a market cap of $1.91 billion, a price-to-earnings ratio of 160.83 and a beta of -2.80. The company’s fifty day simple moving average is $37.94 and its two-hundred day simple moving average is $48.02. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. On average, analysts forecast that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Institutional Trading of Soleno Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Soleno Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Soleno Therapeutics by 50.9% during the first quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock worth $45,236,000 after buying an additional 213,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Soleno Therapeutics by 48.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock worth $2,909,000 after buying an additional 13,211 shares in the last quarter. Creative Planning purchased a new stake in Soleno Therapeutics in the 2nd quarter valued at $338,000. Finally, Legal & General Group Plc raised its position in Soleno Therapeutics by 34.5% in the 2nd quarter. Legal & General Group Plc now owns 35,405 shares of the company’s stock valued at $2,966,000 after buying an additional 9,073 shares during the last quarter. 97.42% of the stock is owned by institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.